Details
Stereochemistry | RACEMIC |
Molecular Formula | C35H53NO3 |
Molecular Weight | 535.8002 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(OC(=O)C3=CN=CC=C3)=C2C
InChI
InChIKey=MSCCTZZBYHQMQJ-AZAGJHQNSA-N
InChI=1S/C35H53NO3/c1-24(2)13-9-14-25(3)15-10-16-26(4)17-11-20-35(8)21-19-31-29(7)32(27(5)28(6)33(31)39-35)38-34(37)30-18-12-22-36-23-30/h12,18,22-26H,9-11,13-17,19-21H2,1-8H3/t25-,26-,35-/m1/s1
DescriptionCurator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664
Curator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664
Tocopherol (alpha tocopheryl nicotinate) is an ester of tocopherol and nicotinic acid. Vitamin E (Tocopherol) is sold commercially as the esterified form (alpha tocopheryl acetate, alpha tocopheryl succinate and alpha tocopheryl nicotinate). Alpha tocopheryl nicotinate has antioxidant and vasodilatory properties. It can be used as a mild warming agent, without producing the redness typical for nicotinic acid. Tocopherol (alpha tocopheryl nicotinate) has been available in Japan since 1967. Tocopherol under the brand name Juvela N is approved in Japan for the treatment of symptoms accompanying hypertension, hyperlipidemia, peripheral circulatory disturbance resulting from arteriosclerosis obliterans. Tocopherol has being shown to inhibit platelet aggregation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070527 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2134664 |
|||
Target ID: GO:0070527 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
|||
Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
|||
Primary | Juvela N Approved UseAccompanying symptoms resulting from the following
Hypertension
Hyperlipidemia
Peripheral circulatory disturbance resulting from the following
Arteriosclerosis obliterans Launch Date1966 |
PubMed
Title | Date | PubMed |
---|---|---|
A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. | 1991 Nov |
|
Final report on the safety assessment of Tocopherol, Tocopheryl Acetate, Tocopheryl Linoleate, Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl Tocopheryl Phosphate, and Tocophersolan. | 2002 |
|
UPLC method for the determination of vitamin E homologues and derivatives in vegetable oils, margarines and supplement capsules using pentafluorophenyl column. | 2014 Dec |
Patents
Sample Use Guides
The usual adult dosage for oral use is 300 - 600 mg of
tocopherol nicotinate (3 - 6 capsules) daily in three divided
doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/835137
177 uM of Tocopherol led to decreased human platelet aggregation in response to the combined ADP and H2O
2
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
51898-34-1
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY | |||
|
27990
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY | |||
|
QCP2FMP7I8
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY | |||
|
DTXSID401019802
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY | |||
|
257-501-4
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY | |||
|
SUB15586MIG
Created by
admin on Fri Dec 15 19:53:21 GMT 2023 , Edited by admin on Fri Dec 15 19:53:21 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD